Last reviewed · How we verify
Dextromethorphan-Bupropion
At a glance
| Generic name | Dextromethorphan-Bupropion |
|---|---|
| Sponsor | Asad Ullah Jan |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- KF2022#4-trial: Effects of a Beta Blocker and NSAID on CYP Mediated Drug Metabolism (NA)
- An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study (PHASE3)
- Drug Interaction Study of ZYN002 Transdermal Gel and Probe Substrates (PHASE1)
- Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE) (PHASE2)
- A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation (PHASE3)
- A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation (PHASE3)
- Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion (PHASE1, PHASE2)
- Efficacy of Dextromethorphan-Bupropion Versus SSRIs in the Treatment of Major Depressive Disorder (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dextromethorphan-Bupropion CI brief — competitive landscape report
- Dextromethorphan-Bupropion updates RSS · CI watch RSS
- Asad Ullah Jan portfolio CI